ALXA News 3.49 08/28/2014 04:30:51 Alexza Pharmaceuticals (A

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Alexza Pharmaceuticals (ALXA) 3.49 $ALXA

Why to Buy These 5 Under-$10 Stocks ASAP
at The Street - Wed Aug 20, 5:00AM CDT
Big-percentage moves are usually in play because their sector is becoming attractive or they have a major fundamental catalyst such as a recent earnings release.

Alexza Pharmaceuticals Provides an Update on the Five Post-EMA Approval Studies for ADASUVE®
PR Newswire - Thu Aug 14, 8:00AM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today provided an update on its European Medicines Agency (EMA) post-approval studies for ADASUVE® inhalation powder, pre-dispensed (loxapine). As part of the ADASUVE approval process with the EMA, Alexza is required to conduct five post-approval studies:

Alexza Pharmaceuticals unveils ADASUVE in Guatemala for schizophrenia or bipolar disorder, reflecting ADASUVE 's first approval in a Latin American country
M2 - Mon Aug 11, 7:22AM CDT
Pharmaceutical company Alexza Pharmaceuticals (NasdaqGM:ALXA) on Friday announced the market availability of ADASUVE inhalation powder, pre-dispensed (loxapine) in Guatemala for treating schizophrenia or bipolar disorder, representing the first ADASUVE approval in Latin America.

Alexza Pharmaceuticals Announces the Launch of ADASUVE® (inhalation powder, loxapine) in Guatemala
PR Newswire - Fri Aug 08, 8:00AM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced that ADASUVE® inhalation powder, pre-dispensed (loxapine) is now available in Guatemala. This approval represents the first ADASUVE approval in Latin America for Ferrer and Alexza. Ferrer is Alexza's commercial partner for ADASUVE in the EU, Latin America and Commonwealth of Independent States countries.

Downgrade Alert for Alexza Pharmaceuticals (ALXA)
Comtex SmarTrend(R) - Fri Aug 08, 7:10AM CDT
Alexza Pharmaceuticals (NASDAQ:ALXA) was downgraded from Buy to Neutral at Roth Capital today. The stock closed yesterday at $4.86 on volume of 66,000 shares, below average daily volume of 121,000. Alexza Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of proprietary products for the treatment of acute and intermittent conditions.

Alexza's net loss widens to USD6.0m in Q2 2014
M2 - Fri Aug 08, 6:43AM CDT
Pharmaceutical company Alexza Pharmaceuticals (NasdaqGM:ALXA) on Thursday disclosed a net loss of USD6.0m for the quarter ended 30 June 2014.

Alexza Reports 2014 Second Quarter Financial Results
PR Newswire - Thu Aug 07, 3:05PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the quarter ended June 30, 2014. The net loss for the second quarter was $6.0 million compared to $0.8 million during the same quarter in 2013. During the three months ended June 30, 2013, Alexza recognized $42.8 million in licensing revenue associated with the signing of the Company's License and Supply Agreement with Teva Pharmaceuticals USA, Inc. The net loss for the six months ended June 30, 2014 and 2013 was $16.7 million and $21.5 million, respectively. At June 30, 2014, Alexza had consolidated cash, cash equivalents, marketable securities and restricted cash of $49.2 million.

Alexza Provides Pipeline Update
PR Newswire - Thu Jul 31, 3:15PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today provided an update on its pipeline and new product development efforts. In the second half of 2014, Alexza expects to initiate a Phase 2a study of AZ-002 (Staccato® alprazolam), which is being developed for the management of patients with acute repetitive seizures. Additionally, Alexza has identified two new Staccato-based product candidates for development - AZ-008 and AZ-009 - which will incorporate the active pharmaceutical ingredient ropinirole, a dopamine agonist, into Alexza's proprietary Staccato system. The Company plans to develop AZ-008 for the acute treatment of restless legs syndrome (RLS) and AZ-009 for hypomobility, or freezing, during "off periods" in Parkinson's disease (PD) patients.

Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences
PR Newswire - Tue Jul 29, 3:15PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it is participating in two healthcare conferences during the third quarter, the 2014 Avondale Partners Healthcare 1-1 Conference and the Morgan Stanley Global Healthcare 2014 Conference. Alexza's corporate presentation will be webcast live from the Morgan Stanley Conference. The details on each event are below:

Alexza to Report 2014 Second Quarter Financial Results on Thursday, August 7, 2014
PR Newswire - Thu Jul 17, 3:15PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) will report results for its fiscal quarter ended June 30, 2014 on Thursday, August 7, 2014, following the close of the U.S. financial markets. The Company will also host an investor conference call and live webcast on the same day at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time to provide a company update and discuss the financial results.

Nasdaq stocks posting largest percentage increases
AP - Thu Jul 17, 12:19PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:

Global Seizures Therapeutics Pipeline Review, H1 2014 - 9 Companies & 12 Drug Profiles
M2 - Tue Jul 01, 9:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ccl3gq/seizures) has announced the addition of the "Seizures - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Seizures, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Seizures and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alexza Pharmaceuticals, Inc. - Novartis AG - Acorda Therapeutics, Inc. - Pfizer Inc. - Upsher-Smith Laboratories, Inc. - Concert Pharmaceuticals, Inc. - Advicenne Pharma - Ultragenyx Pharmaceutical Inc. - Sage Therapeutics Drug Profiles - diazepam - midazolam hydrochloride - everolimus - diazepam - UX-007 - topiramate - alprazolam - ADV-6208 - C-10068 - CCG-63802 - Dihydroxyflavone - SAGE-NCE For more information visit http://www.researchandmarkets.com/research/ccl3gq/seizures

Alexza Announces the Promotion of Edwin S. Kamemoto, Ph.D. to Senior Vice President, Regulatory Affairs
PR Newswire - Mon Jun 30, 3:15PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced the promotion of Edwin S. Kamemoto, Ph.D., to the newly created position of Senior Vice President, Regulatory Affairs. Dr. Kamemoto will have primary responsibility for leading and directing all regulatory affairs and global pharmacovigilence activities.

Alexza Pharmaceuticals closes private placement of USD45m non-recourse notes
M2 - Thu Mar 20, 7:57AM CDT
Central nervous system treatment company Alexza Pharmaceuticals (NasdaqGM:ALXA) revealed on Wednesday the completion of a private placement of USD45.0m of non-recourse notes to institutional investors.

Alexza Pharmaceuticals Announces Private Placement of $45 Million of Non-Recourse Notes
PR Newswire - Wed Mar 19, 8:00AM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) (Alexza) announced today that it has closed a private placement to institutional investors of $45.0 million of non-recourse notes (the "Notes" . The Notes are secured by royalties and potential milestones from U.S. sales of ADASUVE® (loxapine) inhalation powder. Alexza's commercial partner for ADASUVE in the U.S. is Teva Pharmaceuticals USA, Inc.

Alexza Pharmaceuticals and Ferrer Announce the Launch of ADASUVE® (inhalation powder, loxapine) in Romania
PR Newswire - Thu Mar 13, 8:00AM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) and Ferrer today announced that ADASUVE® inhalation powder, pre-dispensed (loxapine) is now available in Romania. Ferrer is Alexza's commercial partner for ADASUVE in the European Union (EU), Latin America and the Commonwealth of Independent States countries. Ferrer is commercializing the product in Romania through a distribution agreement with Galenica, S.A.

Alexza Reports Fourth Quarter and Year End 2013 Financial Results
PR Newswire - Thu Mar 06, 3:05PM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the quarter and year ended December 31, 2013. The net loss for the fourth quarter was $5.7 million compared to $10.3 million during the same quarter in 2012. The net loss for the years ended December 31, 2013 and 2012 was $39.6 million and $28.0 million, respectively. At December 31, 2013, Alexza had consolidated cash, cash equivalents and marketable securities of $25.9 million.

Teva Launches ADASUVE(R) in U.S.
Business Wire - Mon Mar 03, 7:15AM CST
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today the commercial launch of ADASUVE(R) (loxapine) inhalation powder 10 mg, the first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.

Alexza Announces the U.S. Commercial Launch of ADASUVE® by Teva Pharmaceuticals
PR Newswire - Mon Mar 03, 7:07AM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced the U.S. commercial launch of ADASUVE® (loxapine) inhalation powder 10mg by its commercial partner, Teva Pharmaceutical Industries Ltd., (NYSE: TEVA). ADASUVE is the first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.

Robert A. Lippe Joins Alexza Pharmaceuticals as Executive Vice President, Operations and Chief Operations Officer
PR Newswire - Tue Feb 25, 8:00AM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that Robert A. Lippe has joined the Company as Executive Vice President, Operations and Chief Operations Officer. In this newly created position, Mr. Lippe has responsibility for the Company's global operation functions, including strategic development and execution of clinical and commercial manufacturing, quality and compliance, supply chain and supply partner management, technology transfer, facilities, sustainment engineering and IT in support of the Company's product and technology portfolio.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Toledo Crosswalk Death Lawsuit Raises Hard Questions

Updated Category News Views 170

A painted crosswalk is supposed to mean something, and that is the grim center of the lawsuit filed over Judy Tanner’s death in Toledo. Tanner, 20, was walking home from work on September 10, 2026, when she was struck and killed while crossing the street. Her estate is now suing, alleging that the 31-year-old driver failed to yield as Tanner legally used the crosswalk....

Continue Reading
Avelo Tests Loyalty Math With WeSalute Fare Discounts

Updated Category News Views 115

Airline discounts can look like generosity until the load factor starts talking back. Avelo Airlines has joined WeSalute with fare discounts for active-duty military members, veterans, first responders, nurses, medical professionals, public servants, teachers and eligible family members. It is a sensible move for a young carrier built around smaller airports and lower...

Continue Reading
Voltage Energy's Microgrid Launches at RE+ 2026

Updated Category News Views 88

Voltage Energy Unveils New Power Systems In the swirling chaos of energy innovation, Voltage Energy is trying to carve its path at the heart of RE+ 2026. Out in Las Vegas, amidst the buzz of renewable energy tech, they introduced their Microgrid System (MGS) along with two new electrical balance of system (EBOS) products—the Load Break Disconnect Box (LBD) and Combiner...

Continue Reading
Exiger's CEO Honored for Military Support Excellence

Updated Category News Views 10

Recognizing Civilian and Military Leadership When you hear "recognition in the military sector," it isn't just a pat on the back. It's a whole parade of brass hats and high-flyers giving their nods. So, November 10th wasn't just any regular day—Brandon Daniels, CEO of Exiger, gets a shiny, prestigious Five-Star Award for his "extraordinary support" of our military...

Continue Reading
Onward Therapeutics Secures $28M to Bolster Oncology R&D

Updated Category News Views 23

Cashing In to Conquer Cancer In the risk-laden world of biotech, Onward Therapeutics has just bagged a hefty NT$900 million—roughly US$28 million—from its Series B financing. That's not pocket change and speaks to the level of confidence their backers have, even as they plant their global headquarters firmly in Taipei since relocating from Switzerland. A Deep Dive...

Continue Reading
Unishippers Climbs 18 Slots on 32.4% Sales Growth Run

Updated Category News Views 122

Thirty new franchise units can move the needle fast Unishippers did not inch its way up the Franchise Times Top 400; it put up a number that deserves a hard look. Sales rose 32.4% in 2025, the company added 30 franchise units, and the result was an 18-place jump to No. 81 on the 2026 ranking. In the shipping category, it was named the sales-growth leader. For a business...

Continue Reading
Apani Adds Kelsun Assets to Its Natural Fiber Platform

Updated Category News Views 118

A materials deal with more chemistry than chest-thumping Seaweed and cotton have landed under one roof, which is a lot more interesting than another apparel brand slapping a green label on ordinary fabric. Apani said November 17 it acquired the assets of Keel Labs, bringing Keel's seaweed-based Kelsun fiber alongside Apani's enhanced cotton-cellulose filament technology....

Continue Reading
Madrigal Pharmaceuticals Faces Legal Scrutiny Over Data

Updated Category News Views 17

Legal Storm Brews for Madrigal Pharmaceuticals Watch out, here comes another storm for Madrigal Pharmaceuticals, folks. This ain't no small drizzle either; it's a full-on legal monsoon, and it's soaked straight through the walls of their executive suite. We're talking a whistleblower sending alarm bells ringing about data fudging and some dodgy boardroom maneuvers—as if...

Continue Reading
Stand Out For Good Makes a Bold Michigan Avenue Bet

Updated Category News Views 160

A six-floor retail commitment lands with a thud Stand Out For Good is taking on roughly 51,079 square feet at 669 North Michigan Avenue, and nobody should mistake that for a casual expansion. Six levels on Chicago's Magnificent Mile is a proper declaration of intent, especially in a retail district that has endured plenty of empty-window handwringing and big-brand churn....

Continue Reading
Inhabit Puts AI Across Its Property Management Stack

Updated Category News Views 72

Property managers do not need another shiny chatbot; they need fewer dropped leads, fewer invoice-entry mistakes and less staff time burned chasing routine answers. That is the sensible hook in Inhabit's OPTECH 2026 announcement. The company is spreading AI, integrations and scalability work across ResMan, Anyone Home, ePremium, Nationwide Compliant and several adjacent...

Continue Reading

Top 5 Most Recently Viewed Articles

Bladex Reports Impressive Q1 Earnings with Substantial Growth

Updated Category News Views 256

Bladex Financial Performance in Q1 Banco Latinoamericano de Comercio Exterior, S.A. (NYSE: BLX), commonly referred to as Bladex, has announced strong financial outcomes for the first quarter of the year. The bank recorded a net profit of $51.7 million, equating to $1.40 per share, reflecting a year-over-year increase of 1%. This impressive result has contributed to an...

Continue Reading
Opportunities Open Up at Linnet Corner for Seniors

Updated Category News Views 426

Exciting Housing Opportunities for Seniors The Housing Authority of the City of Alameda (AHA) is thrilled to announce the opening of a housing wait list for its newest community, Linnet Corner. Designed specifically for seniors aged 62 and older, this community will offer modern living options in a prime location. With proper access to public transportation, grocery...

Continue Reading
Vistra Corp's Future: Sustaining Growth and Performance

Updated Category News Views 426

Vistra Corp: A Look Ahead at Potential Growth in 2025 Vistra Energy Corp (NYSE: VST) has gained significant attention among investors due to its impressive performance. The company's stock experienced a remarkable 260% increase in value, cementing its position as the second-best performer in its sector. As we begin 2025, Vistra has already displayed positive momentum with...

Continue Reading
Relive Health's New Coral Gables Center Promotes Wellness

Updated Category News Views 346

Relive Health's New Coral Gables Location Set to Energize Wellness Relive Health is excited to announce the grand opening of its latest wellness center in Coral Gables. This expansion reflects the company's commitment to enhancing the health and vitality of communities through cutting-edge wellness solutions. A Comprehensive Wellness Experience This new clinic offers a...

Continue Reading
EssilorLuxottica and Meta Unveil Next-Gen AI Glasses in 2025

Updated Category News Views 456

Exciting Innovations in Wearable Technology EssilorLuxottica and Meta Platforms, Inc. have unveiled their latest advancements in the realm of AI glasses at the recent Meta Connect event. Building on their successful collaboration, these two industry leaders are set to redefine how consumers interact with technology through innovative wearables. The newest models,...

Continue Reading